Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Merck and Co Inc | 1,463 |
| 2 | AstraZeneca PLC | 1,182 |
| 3 | C.H. Boehringer Sohn AG and Co KG | 1,054 |
| 4 | Novartis AG | 1,052 |
| 5 | GSK PLC | 860 |
| 6 | Pfizer Inc | 553 |
| 7 | Procter and Gamble Co | 537 |
| 8 | AbbVie Inc | 535 |
| 9 | Massachusetts Institute of Technology | 524 |
| 10 | Kenvue Inc | 461 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 25,870 |
| 2 | A61K | Medicinal preparations | 25,377 |
| 3 | C07D | Heterocyclic compounds | 13,716 |
| 4 | C07K | Peptides | 3,597 |
| 5 | C12N | Microorganisms, enzymes | 2,297 |
| 6 | A61M | Devices for introducing media into the body | 2,153 |
| 7 | Y02A | Climate change adaptation | 1,972 |
| 8 | C07C | Acyclic and carbocyclic compounds | 1,930 |
| 9 | G01N | Investigating / analysing materials | 1,391 |
| 10 | A61Q | Cosmetics, personal care | 1,200 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Combination dosage form comprising cetirizine and pseudoephedrine | 2001 | Kenvue Inc | 60 |
| Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants | 2002 | Sumitomo Chemical Co Ltd | 45 |
| Solid, rapidly disintegrating cetirizine formulations | 2001 | Viatris Inc | 43 |
| CETIRIZINE-CONTAINING COMPOSITION FOR ANTIALLERGIC EYE DROP AND NASAL DROP | 1994 | Senju Pharmaceutical Co Ltd | 40 |
| Methods for treating allergic disorders using optically pure (-) cetirizine | 1997 | Sumitomo Chemical Co Ltd | 39 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 35 |
| 2017 | 38 |
| 2018 | 33 |
| 2019 | 44 |
| 2020 | 43 |
| 2021 | 28 |
| 2022 | 31 |
| 2023 | 18 |
| 2024 | 31 |
| 2025 | 10 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | J.‐P. Rihoux | UCB Pharma (Belgium) | 18 |
| 2 | Martin K. Church | Southampton General Hospital | 16 |
| 3 | Bernard Burtin | UCB Pharma (Belgium) | 12 |
| 4 | Giorgio Ciprandi | Ospedale Policlinico San Martino | 11 |
| 5 | Giorgio Walter Canonica | University of Genoa | 10 |
| 6 | Torsten Zuberbier | Charité - Universitätsmedizin Berlin | 9 |
| 7 | F. Estelle R. Simons | University of Manitoba | 8 |
| 8 | Maria Angela Tosca | University of Genoa | 7 |
| 9 | Timo Reunala | Tampere University Hospital | 7 |
| 10 | M. Strolin Benedetti | UCB Pharma (France) | 7 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Contamination of surface, ground, and drinking water from pharmaceutical production | 2009 | 1106 | Analytical chemistry methods development |
| Allergic Rhinitis | 2015 | 586 | Allergic Rhinitis and Sensitization |
| Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis | 2004 | 501 | Asthma and respiratory diseases |
| Statistical significant change versus relevant or important change in (quasi) experimental design: some conceptual and methodological problems in estimating magnitude of intervention-related change in health services research | 2002 | 476 | Health Policy Implementation Science |
| The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria | 2010 | 329 | Dermatology and Skin Diseases |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of cetirizine?
Which organizations have the most patent activity related to cetirizine?
What are the most cited patent applications for cetirizine formulations?
What research topics dominate the scientific literature on cetirizine?
How has cetirizine patent filing activity trended in recent years?